Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Conditions: Hormone-receptor-positive Breast Cancer; Premenopausal Breast Cancer; Breast Cancer Patients at Intermediate to High Risk; Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen Interventions: Drug: Aromatase inhibitor; Procedure: ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist); Drug: Tamoxifen; Drug: toremifene Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 6, 2023 Category: Research Source Type: clinical trials
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Condition: Breast Cancer Interventions: Drug: TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen; Drug: Placebo capsules, Letrozole, Anastrozole, Tamoxifen Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2023 Category: Research Source Type: clinical trials
